207 related articles for article (PubMed ID: 37696564)
1. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E; Burgel PR; Hatton A; Bouazza N; Chevalier B; Macey J; Leroy S; Durieu I; Weiss L; Grenet D; Stremler N; Ohlmann C; Reix P; Porzio M; Roux Claude P; Rémus N; Douvry B; Montcouquiol S; Cosson L; Mankikian J; Languepin J; Houdouin V; Le Clainche L; Guillaumot A; Pouradier D; Tissot A; Priou P; Mély L; Chedevergne F; Lebourgeois M; Lebihan J; Martin C; Zavala F; Da Silva J; Lemonnier L; Kelly-Aubert M; Golec A; Foucaud P; Marguet C; Edelman A; Hinzpeter A; de Carli P; Girodon E; Sermet-Gaudelus I; Pranke I;
Eur Respir J; 2023 Oct; 62(4):. PubMed ID: 37696564
[TBL] [Abstract][Full Text] [Related]
2. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
[TBL] [Abstract][Full Text] [Related]
3. Personalized CFTR Modulator Therapy for
Graeber SY; Balázs A; Ziegahn N; Rubil T; Vitzthum C; Piehler L; Drescher M; Seidel K; Rohrbach A; Röhmel J; Thee S; Duerr J; Mall MA; Stahl M
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569738
[TBL] [Abstract][Full Text] [Related]
4. CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare
Lefferts JW; Bierlaagh MC; Kroes S; Nieuwenhuijze NDA; Sonneveld van Kooten HN; Niemöller PJ; Verburg TF; Janssens HM; Muilwijk D; van Beuningen SFB; van der Ent CK; Beekman JM
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833986
[TBL] [Abstract][Full Text] [Related]
5. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del
Burgel PR; Sermet-Gaudelus I; Durieu I; Kanaan R; Macey J; Grenet D; Porzio M; Coolen-Allou N; Chiron R; Marguet C; Douvry B; Dufeu N; Danner-Boucher I; Foucaud P; Lemonnier L; Girodon E; Da Silva J; Martin C;
Eur Respir J; 2023 Feb; ():. PubMed ID: 36796836
[TBL] [Abstract][Full Text] [Related]
6. CFTR Modulators Rescue the Activity of CFTR in Colonoids Expressing the Complex Allele p.[R74W;V201M;D1270N]/dele22_24.
Kleinfelder K; Somenza E; Farinazzo A; Conti J; Lotti V; Latorre RV; Rodella L; Massella A; Tomba F; Bertini M; Sorio C; Melotti P
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982273
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects of Elexacaftor/Tezacaftor/Ivacaftor in people with CF carrying non-F508del mutations.
Livnat G; Dagan A; Heching M; Shmueli E; Prais D; Yaacoby-Bianu K; Stein N; Mei-Zahav M; Gur M; Cohen-Cymberknoh M; Shteinberg M
J Cyst Fibros; 2023 May; 22(3):450-455. PubMed ID: 36372699
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
10. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
11. Q1291H-CFTR molecular dynamics simulations and
Allan KM; Astore MA; Kardia E; Wong SL; Fawcett LK; Bell JL; Visser S; Chen PC; Griffith R; Jaffe A; Sivam S; Vittorio O; Kuyucak S; Waters SA
Front Mol Biosci; 2023; 10():1148501. PubMed ID: 37325471
[No Abstract] [Full Text] [Related]
12. Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
Zhang S; Shrestha CL; Robledo-Avila F; Jaganathan D; Wisniewski BL; Brown N; Pham H; Carey K; Amer AO; Hall-Stoodley L; McCoy KS; Bai S; Partida-Sanchez S; Kopp BT
Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36265882
[TBL] [Abstract][Full Text] [Related]
13. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
Laselva O; Bartlett C; Gunawardena TNA; Ouyang H; Eckford PDW; Moraes TJ; Bear CE; Gonska T
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303536
[TBL] [Abstract][Full Text] [Related]
14. L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients.
Lo Cicero S; Castelli G; Blaconà G; Bruno SM; Sette G; Pigliucci R; Villella VR; Esposito S; Zollo I; Spadaro F; Maria R; Biffoni M; Cimino G; Amato F; Lucarelli M; Eramo A
Respir Res; 2023 Sep; 24(1):217. PubMed ID: 37674160
[TBL] [Abstract][Full Text] [Related]
15. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
16. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
17. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
Milo F; Ciciriello F; Alghisi F; Tabarini P
J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
[TBL] [Abstract][Full Text] [Related]
18. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
Shaughnessy CA; Zeitlin PL; Bratcher PE
J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
[TBL] [Abstract][Full Text] [Related]
19. Theratyping of the Rare CFTR Genotype A559T in Rectal Organoids and Nasal Cells Reveals a Relevant Response to Elexacaftor (VX-445) and Tezacaftor (VX-661) Combination.
Kleinfelder K; Villella VR; Hristodor AM; Laudanna C; Castaldo G; Amato F; Melotti P; Sorio C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373505
[TBL] [Abstract][Full Text] [Related]
20. Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.
Jordan KD; Zemanick ET; Taylor-Cousar JL; Hoppe JE
Expert Rev Respir Med; 2023 Feb; 17(2):97-108. PubMed ID: 36803356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
